aflibercept intravitreal (Rx)

Brand and Other Names:Eylea
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

injectable solution for intravitreal use

  • 2mg/0.05mL (40mg/mL single-dose vial)
  • 2mg/0.05mL (40mg/mL single-dose prefilled syringe)

Macular Degeneration

Indicated for treatment of neovascular (wet) age-related macular degeneration (AMD)

2 mg (0.05 mL) by intravitreal injection q4Week for the first 3 injections, followed by 2 mg q8Week (~ every 2 months)

Some patients may need to be dosed as frequently as 2 mg q4Weeks (~ every 25 days, monthly), additional efficacy was not demonstrated in most patients when dosed q4Weeks compared to q8Weeks

Although not as effective as the recommended q8Week dosing regimen, after 1 year of effective therapy, may treat with 1 dose q12Weeks

Macular Edema

Indicated for treatment of macular edema following retinal vein occlusion (RVO) (branched or central retinal vein occlusion)

2 mg (0.05 mL) by intravitreal injection q4Week (~ every 25 days, monthly)

Diabetic Macular Edema (DME)

2 mg (0.05 mL) administered by intravitreal injection q4Week for the first 5 injections, followed by 2 mg q8Week

May be dosed as frequently as 2 mg q4Week; however, additional efficacy was not demonstrated when dosed q4Week compared to q8Week

Some patients may need q4Week (monthly) dosing after first 20 weeks (5 months)

Diabetic Retinopathy

2 mg (0.05 mL) administered by intravitreal injection q4Week for the first 5 injections, followed by 2 mg q8Week

May be dosed as frequently as 2 mg q4Week; however, additional efficacy was not demonstrated when dosed q4Week compared to q8Week

Some patients may need q4Week (monthly) dosing after first 20 weeks (5 months)

Safety and efficacy not established

Next:

Adverse Effects

>10%

Conjunctival hemorrhage (25%)

Eye pain (9-13%)

1-10%

Cataract (7%)

Vitreous floaters (6%)

Increased IOP (5%)

Conjunctival hyperemia (4%)

Corneal erosion (4%)

Retinal pigment epithelium detachment (3%)

Injection site pain (3%)

Foreign body sensation in eyes (3%)

Lacrimation increased (3%)

Blurred vision (2%)

Retinal pigment epithelium tear (2%)

Injection site hemorrhage (1%)

Eyelid edema (1%)

Corneal edema (1%)

Postmarketing Reports

Hypersensitivity

Endophthalmitis and retinal detachments

Increase in intraocular pressure

Thromboembolic events

Previous
Next:

Warnings

Contraindications

Hypersensitivity reactions

Ocular or periocular infection

Active intraocular inflammation

Cautions

Endophthalmitis and retinal detachments reported with intravitreal injections

Acute increases in intraocular pressure (IOP) observed within 60 minutes of intravitreal injection; sustained increases also reported after repeat dosing; monitor and manage IOP and perfusion of optic nerve head

Potential risk of arterial thromboembolic events (eg, nonfatal stroke, nonfatal myocardial infarction, or vascular death) following intravitreal use of VEGF inhibitors (incidence over 1 yr varies depending on the study ranging from 1.5-6.4%); no thromboembolic events reported within the first 6 months of RVO studies

Hypersensitivity reactions may present as severe intraocular inflammation

Females of reproductive potential should use effective contraception prior to initial dose, during treatment, and for at least 3 months after last intravitreal injection

Previous
Next:

Pregnancy & Lactation

Pregnancy

Adequate and well-controlled studies have not been conducted in pregnant women; aflibercept produced adverse embryofetal effects in rabbits, including external, visceral, and skeletal malformations

Animal reproduction studies not always predictive of human response; not known whether product can cause fetal harm when administered to pregnant woman; based on anti-VEGF mechanism of action for aflibercept, treatment may pose a risk to human embryofetal development

Contraception

  • Females of reproductive potential are advised to use effective contraception prior to initial dose, during treatment, and for at least 3 months after last intravitreal injection

Infertility

  • There are no data regarding effects on human fertility; aflibercept adversely affected female and male reproductive systems in cynomolgus monkeys when administered by intravenous injection at a dose approximately 1500 times higher than systemic level observed humans with an intravitreal dose of 2 mg; a No Observed Adverse Effect Level (NOAEL) was not identified; aflibercept produced fetal malformations at all doses assessed in rabbits and the fetal NOAEL was <0.1 mg/kg; findings were reversible within 20 weeks after cessation of treatment

Lactation

There is no information regarding presence of aflibercept in human milk, effects on breastfed infant, or on milk production/excretion; because many drugs are excreted in human milk, and potential for absorption and harm to infant growth and development exists, therapy is not recommended during breastfeeding

Developmental and health benefits of breastfeeding should be considered along with mother's clinical need for therapy and potential adverse effects on breastfed child

Pregnancy Categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

Previous
Next:

Pharmacology

Mechanism of Action

Binds and prevents activation of vascular endothelial growth factors (VEGF-A) and placental growth factor (PIGF)

Activation of VEGF-A and PIGF can result in neovascularization and vascular permeability

Absorption

Peak plasma time: 1-3 days

Peak plasma concentration: 0.02 mcg/mL

Distribution

Vd: 6 L

Elimination

Half-life: 5-6 days

Previous
Next:

Administration

Intravitreal injection preparation

Vial

  • Vial contains 0.278 mL of 40 mg/mL solution
  • Use provided 5-micron filter needle
  • Withdraw all contents of vial (keep vial in upright position, slightly inclined to ease complete withdrawal)
  • Remove and discard filter needle
  • Replace needle with 30-gauge x 0.5-inch needle (provided in kit)
  • Gently tap syringe to remove bubbles; expel air and set dose
  • Each vial should only be used for a single eye

Prefilled syringe

  • Attach 30-gauge x 0.5-inch needle (provided in kit)
  • Gently tap syringe to remove bubbles; expel air and set dose
  • Each prefilled syringe should only be used for a single eye

Intravitreal administration

Intravitreal injection should be done under aseptic conditions, which include surgical hand disinfection and the use of sterile gloves, a sterile drape, and a sterile eyelid speculum (or equivalent).

Prior to injection, adequate anesthesia and a topical broad–spectrum microbicide

Monitor patient immediately following administration for elevation in intraocular pressure

Appropriate monitoring may consist of a check for perfusion of the optic nerve head or tonometry

If required, a sterile paracentesis needle should be available

If contralateral eye requires treatment, use a new sterile prefilled syringe or vial and change the sterile field, syringe, gloves, drapes, eyelid speculum, filter, and injection needles before administration to the other eye

After injection, discard any unused product

Storage

Refrigerate unopened vials or prefilled syringes at 2-8°C (36-46°F); do not freeze

Protect from light

Store in the original carton until time of use

Previous
Next:

Images

Previous
Next:

Formulary

FormularyPatient Discounts

Adding plans allows you to compare formulary status to other drugs in the same class.

To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

Adding plans allows you to:

  • View the formulary and any restrictions for each plan.
  • Manage and view all your plans together – even plans in different states.
  • Compare formulary status to other drugs in the same class.
  • Access your plan list on any device – mobile or desktop.

The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

Tier Description
1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
NC NOT COVERED – Drugs that are not covered by the plan.
Code Definition
PA Prior Authorization
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
QL Quantity Limits
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
ST Step Therapy
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
OR Other Restrictions
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Additional Offers
Email to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Email Forms to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.